
Opinion|Videos|August 26, 2024
Advancements in MIST for BPH: Options, Guidelines, and Patient-Centered Decision-Making
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, covers minimally invasive surgical therapies (MIST) for BPH, including laser therapy, prostatic urethral lift, and others, their impact on BPH management, AUA guidelines, patient selection, and the role of patient preference in choosing between MIST, medication, and surgery.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Can you please provide a high-level overview of the following available minimally invasive surgical therapies (MIST) options for benign prostate dysplasia (BPH) and how they work?
- Laser therapy
- Prostatic urethral lift procedure
- Water vapor thermal therapy
- Robotic waterjet treatment
- Photoselective vaporization of the prostate
- Any other novel therapeutic options
- How has the emergence of MIST impacted the management of patients with BPH?
- What are the current American
Urological Association guidelines/recommendations for MIST? - Which patients make good candidates for MIST options?
- When/why do you consider a MIST vs surgery (patient prognosis, patient preference, comorbidities)?
- What role does patient preference play in choosing medication vs surgery vs a MIST? Please speak to the importance of shared decision-making.
Advertisement
Related to this article

The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.

The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.

Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.

Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC

EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.

Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
Advertisement
Advertisement
Trending on Urology Times
1
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
2
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
3
Topical sildenafil cream associated with lower systemic exposure vs oral sildenafil
4
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
5

